On Wednesday, GTT Communications Inc (NYSE:GTT)’s shares inclined 4.86% to $24.80.
GTT Communications, Inc. (GTT), the leading global cloud networking provider to multinational clients, declared a definitive agreement to acquire One Source Netoperates (OSN), a provider of global data, Internet, Session Initiation Protocol (SIP) trunking and managed services to Fortune 1000 companies.
This combination:
- Extends GTT’s worldwide network reach through the addition of new points-of-presence.
- Expands GTT’s cloud networking services, counting SIP trunking and other enterprise Voice over IP (VoIP) services.
- Enhances GTT’s multinational client base and adds deep talent to its sales force.
GTT Communications, Inc. operates as an Internet Protocol (IP) based networking company. It offers private, public, and hybrid cloud networking; high bandwidth IP transit for content delivery and hosting applications; on-demand and high-demand network capacity to support varying needs; and network-to-network carrier interconnects.
Kilroy Realty Corp (NYSE:KRC)’s shares gained 1.13% to $67.15.
Kilroy Realty Corporation (KRC), declared that its board of directors declared a regular quarterly cash dividend of $0.35 per common share payable on October 14, 2015 to stockholders of record on September 30, 2015. The dividend is equivalent to an annual rate of $1.40 per share.
The board of directors also declared a dividend of $0.4296875 per share on the company’s 6.875% Series G Cumulative Redeemable Preferred Stock for the period commencing on and counting August 15, 2015 up to and counting November 14, 2015. The dividend will be payable on November 15, 2015 to Series G preferred stockholders of record on October 31, 2015. As October 31, 2015 falls on a Saturday, the effective record date for the dividend will be Friday, October 30, 2015.
Kilroy Realty Corporation is a privately owned real estate investment trust. The firm engages in investment, development, and administration of properties. It invests in the real estate markets of Southern California. The firm’s portfolio comprises office, industrial, R&D, and multi-purpose properties. The company was founded in 1947 and is based in Los Angeles, California.
At the end of Wednesday’s trade, Owens & Minor, Inc. (NYSE:OMI)‘s shares surged 0.44% to $34.54.
Owens & Minor, Inc. (OMI) declared that it has named W. Marshall Simpson to serve as Executive Vice President & Chief Commercial Officer, effective October 4, 2015. Simpson, who was most recently Chief Executive Officer of Dominions Medical, a consulting firm he founded to advise new and existing medical and technology companies, served for twenty years at Owens & Minor. After starting his career at Owens & Minor as a sales representative in 1991, Simpson worked in a variety of roles at Owens & Minor, eventually serving as Senior Vice President, Sales, Operations & Marketing from 2007 to 2011. Simpson, whose appointment was approved by the company’s board of directors, will serve on the leadership team of P. Cody Phipps, Owens & Minor’s new President & Chief Executive Officer.
During his time at Owens & Minor, Simpson was instrumental in the growth of the company and in expanding its reach throughout the domestic healthcare industry. His expertise, knowledge of the healthcare industry, relationships with major players in healthcare, and his close association with Owens & Minor over two decades will greatly benefit the company. In his new role at Owens & Minor, Simpson is charged with developing a domestic sales and marketing strategy that leverages the company’s extensive logistics network and customer relationships, encompassing the full spectrum of manufacturer and provider service offerings.
Owens & Minor, Inc., together with its auxiliaries, operates as a healthcare logistics company. It operates through two segments, Domestic and International. The company offers supply chain assistance to the providers of healthcare services; and the manufacturers of healthcare products, supplies, and devices.
RXi Pharmaceuticals Corp (NASDAQ:RXII), ended its Wednesday’s trading session with 3.07% gain, and closed at $0.470.
RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, recently declared that Dr. Geert Cauwenbergh, RXi’s President and CEO, will be participating in the forthcoming 15th Annual Biotech in Europe Forum for Global Partnering and Investment Conference, with an oral presentation and panel talk about. This Forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life sciences industry.
On Tuesday, September 29, 2015 from 12:00 to 1:00 p.m. CEST, Dr. Cauwenbergh will talk about the development and partnering strategy for RXi’s proprietary self-delivering RNAi (sd-rxRNA®) platform during a panel talk about entitled Platform Technologies & Novel Therapeutics.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
